Business Context and Reporting Period
Boundless Bio, Inc. (Nasdaq: BOLD), a Delaware corporation, filed this Form 8-K on April 1, 2025. The report details the entry into a material definitive agreement to facilitate the sale of common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a current report regarding a corporate transaction rather than a periodic financial statement.
Material Changes and Agreements
- Open Market Sale Agreement: On April 1, 2025, the Company entered into an agreement with Jefferies LLC to sell shares of common stock in "at the market offerings."
- Offering Capacity: The Company may sell shares with an aggregate offering price of up to $14.5 million.
- Compensation: Jefferies LLC will receive a commission of up to 3.0% of the gross proceeds from any shares sold.
- Terms: Sales will be made at prevailing market prices. Neither party is obligated to sell or buy shares, and the agreement may be terminated by either party upon specified written notice.
- Registration: Shares will be issued pursuant to a Form S-3 registration statement filed on April 1, 2025, subject to SEC effectiveness.
Guidance, Outlook, and Risks
The filing contains no financial guidance or management commentary on future performance. Key contingencies and risks include:
- No assurance exists that the Company will sell any shares under the agreement.
- If sales occur, the price, amount, and timing are uncertain.
- The Company has agreed to indemnify Jefferies LLC against certain liabilities under the Securities Act of 1933 and the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the effectiveness status of the Form S-3 registration statement filed on April 1, 2025.
- Monitor future filings for actual sales activity, proceeds raised, and dilution impact.
- Review the full text of the Open Market Sale Agreement (Exhibit 1.1) for specific termination rights and indemnification limits.
- Check the Company's current cash position to assess the necessity of this capital raise.